Research
Hormonal
Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.
Tirzepatide may be considered for patients seeking substantial weight loss.
StrongSupportsmedium confidence
Tirzepatide...has recently demonstrated that body weight reduction exceeding 20% in people with obesity and coupled with improved cardiometabolic measures is feasible.
Why this rating
The claim is based on recent clinical findings regarding a specific medication.
Source
New insights into the treatment of obesity
Matthias Blüher et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15077
reviewCited 142×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.Strong
- There is a need for the development of highly efficacious and safe new agents for obesity treatment.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →